Daniele Cattaneo

Real-world Italian experience with asciminib in chronic myeloid leukaemia–chronic phase: case series and drug profile overview

Abstract Asciminib selectively targets the myristoyl pocket of ABL1, offering high specificity and a potentially improved safety profile. Its efficacy has been demonstrated in both clinical trials and real-world settings, including heavily pretreated patients and those with T315I...